Important Resolutions of AGM 2017
Date of the meeting: June 28, 2017 Resolution #1: The 2016 earning distribution and expense appropriation was recognized. Resolution #2: Amended items—None Resolution #3: The 2016 Annual report and financial …
Supplemental information on the approved application of Phase III clinical trial of OBI-822, the novel breast cancer drug, in China, US, and the EU
Date of occurrence: June 11, 2017 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): N/A Reciprocal shareholding ratios: N/A Name of mass …
Serum N-glycome characterization and anti-carbohydrate antibody profiling in oral squamous cell carcinoma patients
Glycosylation is a protein post translational modification which plays important role in protein function, stabilization, trafficking, and turnover. Alteration of protein glycosylation is a common phenomenon during tumor progression, migration, …
OBI Pharma Announces Acquisition of TH-3424 from Threshold Pharmaceuticals
OBI Pharma to develop OBI-3424 (previously TH-3424) as a potential treatment of cancers expressing AKR1C3. Taipei, Taiwan, June 1, 2017 — OBI Pharma, Inc., a Taiwan biopharma company (TPex: 4174), …
OBI Pharma Announces Acquisition of the Novel First-in-class Anti-Cancer Drug OBI-3424 from Threshold Pharmaceuticals to be Developed as Potential Anti-Cancer Therapy for Cancers with High AKR1C3
Date of occurrence: June 01, 2017 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): N/A Reciprocal shareholding ratios: N/A Name of mass …
Announcement of explanation on the first instance judgment of the civil action between the Company against “Next Magazine”
Parties to the legal matter: Plaintiff: OBI Pharma, Inc. Defendant: Next Digital Ltd., Hong Kong (”Next@Digital”) Name of the court or disposing agency: Taipei District Court, Taiwan Reference/case numbers of …
Announcement of explanation on the Company’s criminal lawsuit against Next Magazine
Parties to the legal matter: OBI Pharma, Inc. Name of the court or disposing agency: Shihlin District Prosecutors Office, Taiwan Reference/case numbers of relevant documents: 2017 Zhen-Zi No. 5025, 5026 …
OBI-833, the cancer therapeutic vaccine, has met the primary safety indicators in Phase I clinical trial for US and Taiwan
Date of occurrence of the event: April 6, 2017 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): head office Reciprocal shareholding ratios: …
The board of directors have resolved not to distribute dividends
Date of the board of directors resolution : 9 Mar 2017 (1) Appropriations of earnings in cash dividends to shareholders (NT$ per share): 0 (2) Cash distributed from legal reserve …
Announcement by the Company’s Board of Directors to convene the 2016 Annual General Shareholders’ meeting
Date of the board of directors resolution: Thursday 9 March 2017 Date for convening the shareholders’ meeting: Wednesday 28 June 2017 Location for convening the shareholders’ meeting: 11F., #97, Dunhua …